PBYI Q3 2021 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M-8.9% YoY

Gross Profit

$36M77.8% margin

Operating Income

-$9M-19.4% margin

Net Income

-$45M-96.6% margin

EPS (Diluted)

$-1.09

QoQ Revenue Growth

-13.4%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$10M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$226M

Total Liabilities

$237M

Stockholders' Equity

-$11M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$51M	-8.9%
Gross Profit	$36M	$41M	-11.9%
Operating Income	-$9M	-$12M	+26.2%
Net Income	-$45M	-$31M	-42.0%

Revenue Segments

Product

$43M94%

Royalty

$3M6%